Evidence from Europe, for example, has demonstrated the cost-effectiveness of polypill strategies containing aspirin, statins, and renin–angiotensin system inhibitors in patients with established cardiovascular disease, supporting its integration into guidelines and clinical pathways (33, 34, 35, 36). The gene discussed is REN; the disease is cardiovascular disorder.